Global Trichomoniasis Drugs Market, By Drug Type (Metronidazole, Tinidazole), Product Type ((Tablet, Suppository/Pessaries, Cream, IV), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Trichomoniasis Drugs Market Analysis and Size
In the U.S., the cases of trichomoniasis were around 2,570,002 in 2017. Furthermore, the gender-specific cases of trichomoniasis were maximum among females and were stated to be 2,073,893 in the country. In the U.S., around 70% of the trichomoniasis cases are asymptomatic. Increase in cases of unprotected sex has led to the increased spread of the disease.
Data Bridge Market Research analyses a growth rate in the trichomoniasis drugs market in the forecast period 2023-2030. The expected CAGR of trichomoniasis drugs market tends to be around 4.50% in the mentioned forecast period. The market was valued at USD 63.2 billion in 2022 and would grow to USD 90 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Trichomoniasis Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Type (Metronidazole, Tinidazole), Product Type ((Tablet, Suppository/Pessaries, Cream, IV), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Lupin (India), Teva Pharmaceuticals Industries Ltd. (Israel), Zydus Group (India), Bausch Health Companies Inc (Canada), Missionpharma A/S (Denmark) and Zauba Technologies & Data Services Private Limited (India), Mission Pharmacal Company (U.S.), Unique Pharmaceuticals Limited.(Africa), Edenbridge Pharmaceuticals, LLC (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Trichomoniasis is a sexually transmitted disease (STD) which is caused by the flagellated protozoan parasite that is transmitted from one person to another during intercourse. The parasite usually transmits from a vagina to a penis or from penis to a vagina, and many times, from a vagina to another vagina. Men and women are both suffering from trichomoniasis globally and the commonly infected part of the body in women is the lower genital tract such as cervix, vagina, vulva, or urethra, while that in men is the inside of the penis.
Trichomoniasis Drugs Market Dynamics
Drivers
- Increase in Trichomoniasis
Rise in the occurrence rate of Trichomoniasis disease is one of the primary factors for the growth of the market. In 2020, WHO witnessed 374 million new cases of STIs globally out of which 176 million new cases of trichomoniasis are found all over the world and the increasing in public awareness about STDs. Rise in R&D activities associated with discovering an effective therapy for the condition are the major drivers for the growth of the market.
- Increased Drug Approvals
The increasing number of drug launches and approvals lead to the growth of the market. For instance, on 28 January 2022, Glenmark Pharmaceuticals Inc., US received final approval from the FDA for Metronidazole Vaginal Gel, 0.75%, the generic version of MetroGel-Vaginal1 Gel, 0.75%, of Bausch Health US, LLC. Furthermore, on 6 September 2021, Aleor Dermaceuticals received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Metronidazole Gel USP, 1%. Thus, this boosts the market growth.
Opportunities
- Growing Acquisitions by Different Market Players
The increasing number of acquisitions that are led by numerous market players lead to the growth of the market. For instance, on 29 March 2022, Alembic Pharmaceuticals Ltd fully acquired Aleor Dermaceuticals Limited. Aleor Dermaceuticals provides products in many of formulations, which includes creams, micro sponge, gels, shampoos, lotions, ointments, solutions, sprays, foams, and platform-based nanoparticle products and this acquisition will further increase capability of Alembic pharma in manufacturing and marketing products of various skin related diseases
Restraints/Challenges
- Increased Awareness About Sexually Transmitted Diseases
Increase in awareness about the spread of sexually transmitted diseases such as HIV and rising need of evading them by using preventive measures such as use of condoms can diminish the incidence of STD leading to delaying revenue growth of the market.
This trichomoniasis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the trichomoniasis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Trichomoniasis Drugs Market Scope
The trichomoniasis drugs market is segmented on the basis of drug type, product type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Type
- Metronidazole
- Tinidazole
Product Type
- Tablet
- Suppository/Pessaries
- Cream
- IV
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Trichomoniasis Drugs Market Regional Analysis/Insights
The trichomoniasis drugs market is analyzed and market size insights and trends are provided by drug type, product type, distribution channel and end-user as referenced above.
The major countries covered in the trichomoniasis drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market due to rise in the better health care infrastructure, rise in the economic growth, rise in the growth of the private health care sector and increase in awareness among people in this region.
Asia-Pacific dominates the market due to increase in the number of insurance payers and rise in the growth of the private health care sector in these regions.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Trichomoniasis Drugs Market Share Analysis
The trichomoniasis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to trichomoniasis drugs market.
Key players operating in the trichomoniasis drugs market include:
- Pfizer Inc. (U.S.)
- Lupin (India)
- Teva Pharmaceuticals Industries Ltd. (Israel
- Zydus Group (India)
- Bausch Health Companies Inc (Canada)
- Missionpharma A/S (Denmark)
- Zauba Technologies & Data Services Private Limited (India)
- Mission Pharmacal Company (U.S.)
- Unique Pharmaceuticals Limited.(Africa)
- Edenbridge Pharmaceuticals, LLC (U.S.)
SKU-